Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Jules Bordet Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06150898CT.gov Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) | — | Recruiting | — | — | — |
NCT05732064CT.gov Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality | — | Completed | — | — | — |
NCT03407430CT.gov Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain | — | Terminated | — | — | — |
NCT02024568CT.gov Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia | — | Unknown | — | — | — |
NCT00702949CT.gov Pregabalin in Treating Women With Hot Flashes | — | Completed | — | — | — |
NCT00852683CT.gov The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pregabalin (this asset) | Jules Bordet Institute | Approved | B · 63 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Pregabalin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | A · 82 |
| Peripheral Neuropathy | — | P4 | A · 82 |
| Postherpetic Neuralgia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pregabalin in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pregabalin-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →